|
Title
|
|
|
|
Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| SETTING: To assess the revised World Health Organization-recommended dose of 10-20 mg/kg rifampicin (RMP), we studied the steady state pharmacokinetics of RMP in South African children who received standard treatment for drug-susceptible tuberculosis (TB). OBJECTIVE: To determine the formulation effect on the pharmacokinetics of RMP. DESIGN: RMP plasma concentrations were characterised in 146 children (median age 1.4 years, range 0.2-10.2). The morning dose on the day of the pharmacokinetic evaluation was administered as one of two RMP single-drug oral suspensions. RESULTS: While one formulation achieved 2 h concentrations in the range of those observed in adults (median 6.54 mg/l, interquartile range [IQR] 4.47-8.84), the other attained a median bioavailability of only 25% of this, with a median 2 h concentration of 1.59 mg/l (IQR 0.89-2.38). CONCLUSION: RMP is a key drug for the treatment of TB. It is critical that the quality of RMP suspensions used to treat childhood TB is ensured. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
International journal of tuberculosis and lung disease. - Paris
|
|
|
Publication
|
|
|
|
Paris
:
2016
|
|
|
ISSN
|
|
|
|
1027-3719
|
|
|
DOI
|
|
|
|
10.5588/IJTLD.15.0833
|
|
|
Volume/pages
|
|
|
|
20
:7
(2016)
, p. 915-919
|
|
|
ISI
|
|
|
|
000378189200014
|
|
|
Pubmed ID
|
|
|
|
27287644
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|